• AUM grants Newsoara exclusive license in oncology for current and future pipeline for up to 6 oncology molecules in the Greater China Region
• AUM will receive up to $135M in Near-term Development, Regulatory, and Commercial milestones for its current pipeline. Additionally, AUM will be eligible to receive up to Double Digit Royalty Payments
• AUM and Newsoara will co-discover up to 5 first-in-class programs that target critical biological pathways
• AUM retains worldwide ex-Greater China rights, and Newsoara retains Greater China rights for all newly discovered candidates
• AUM expands its access to the world renowned Suzhou biotech ecosystem, and boosts its strong discovery and significant manufacturing capabilities in Suzhou BioBAY to drive its �Asia to Global� strategy

SINGAPORE--(BUSINESS WIRE)--#Asiatoglobal--AUM Biosciences (AUM), a global, clinical stage healthcare company focused on discovering, acquiring and developing novel oncology therapeutics and Newsoara Biopharma announced today that the companies have entered into a 5-year strategic partnership to co-develop up to 6 oncology drugs in AUM�s pipeline.

The partnership combines AUM�s world-class discovery and clinical development capabilities with Newsoara�s strong discovery, development, and manufacturing capabilities in China.

Under the terms of the Agreement, AUM will receive an undisclosed collaboration fee upon closing. AUM will license exclusive greater China rights of AUM001, AUM302 and AUM003 upon closing of this Agreement, and up to a further 3 candidates for a maximum of 6 oncology drugs.

AUM will receive up to $135 Million in near term development, regulatory, commercial milestones and up to double-digit royalty payments. Newsoara will be responsible for all development and commercialisation and will contribute for potential R&D funding for current and future investigational compounds in greater China.

AUM and Newsoara will co-discover and co-fund first-in-class therapeutics for mutually agreed novel targets. AUM retains worldwide rights ex-greater China and Newsoara retains greater China rights for these newly discovered compounds.

Newsoara�s CEO, Benny Li will join AUM�s Board of Directors.

�Newsoara is an ideal partner for AUM with its focus to provide novel and differentiated therapies for unmet medical needs in China ,� said Vishal Doshi, CEO, AUM Biosciences. �This collaboration is foundational for AUM and will allow us to act as one team to maximize the clinical and commercial potential of AUM�s molecules, greatly amplifying and expediting the opportunities in our pipeline. This partnership accelerates AUM�s path to becoming an independent, fully integrated biopharmaceutical company.�

AUM is building a diverse portfolio of small molecule therapeutics that target critical biological pathways. A core component of AUM�s strategy is mandating biomarkers and leveraging AI to systematically discover and develop targeted cancer therapies. Additionally, AUM has a strong focus on the development of intra-portfolio combinations that include small molecules. Through its �Asia to Global� Strategy, including this partnership, AUM will expedite drug development to meet unmet medical needs for patients globally.

�We are very pleased to build on Newsoara�s growing presence in China with this important new strategic collaboration with AUM,� said Benny Li, CEO, Newsoara Biopharma. �Newsoara is committed to developing first-in-class programs for patients and our agreement with AUM further demonstrates that commitment. By gaining access to each other�s diverse pipeline and AUM�s clear strengths and world-class experts in discovery and development, we believe that our partnership with AUM will significantly accelerate our progress in developing next generation therapies for patients.�

About AUM Biosciences

AUM is a clinical-stage biopharmaceutical company with a focus on discovering, acquiring, and developing novel therapeutics in oncology. AUM utilizes AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.

About Newsoara

Newsoara is an innovative clinical-stage biopharmaceutical company with a mission to develop and commercialize life changing medicines for cancer, autoimmune, metabolic and other major diseases to patients in China and around the world. Since its founding, Newsoara has developed a fully integrated platform which includes R&D, CMC and clinical development capabilities and built a robust and broad pipeline of 15 drug candidates in major therapeutics areas. Newsoara has assembled a world-class management team with extensive experience in innovative drug development that is motivated to improve and impact human health worldwide.

Contacts

AUM Biosciences:
Investor Relations & Communications:

Name: Terig Hughes, CFO

T: +65 68086034

Email: [email protected]
Website: www.aumbiosciences.com